A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
NCT ID: NCT03017014
Last Updated: 2020-10-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
62 participants
OBSERVATIONAL
2017-09-26
2019-10-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
NCT02130362
Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease
NCT00409682
Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806
NCT00686374
Remission in Subjects With Crohn's Disease, 1 Year Phase
NCT00055497
Control Crohn Safe Trial
NCT03917303
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pediatric participants receiving adalimumab
Pediatric participants receiving adalimumab for CD in real-life conditions.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adalimumab-naïve patient (a patient having received an anti-TNF other than adalimumab may enter the study)
* Starting a treatment with adalimumab
* Guardian capable of and willing to grant authorization for use/disclosure of data collected and patient able to comply with the requirements of the study protocol.
Exclusion Criteria
* Participants enrolled in a concomitant interventional clinical trial.
6 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AbbVie Inc.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Lyon Sud /ID# 152667
Pierre-Bénite, Auvergne-Rhône-Alpes, France
Centre Hospitalier Lyon Sud /ID# 152668
Pierre-Bénite, Auvergne-Rhône-Alpes, France
Hopital Clocheville /ID# 152831
Tours, Centre-Val de Loire, France
CHU de Besancon - Jean Minjoz /ID# 154197
Besançon, Doubs, France
Hopitaux de Brabois Adultes /ID# 152729
Vandœuvre-lès-Nancy, Lorraine, France
CHU Toulouse /ID# 153251
Toulouse, Occitanie, France
CHU Batiment Robert Debre /ID# 152665
Angers, , France
CHU Bordeaux-Hopital Pellegrin /ID# 154620
Bordeaux, , France
Chu de Bordeaux Hopital /Id# 157926
Bordeaux, , France
Centre Hospitalier Universitai /ID# 155465
Caen, , France
CHU Hopital d'Estaing /ID# 152664
Clermont-Ferrand, , France
Hopital Jeanne de Flandre /Id# 155464
Lille, , France
Hopital de la Timone /ID# 160133
Marseille, , France
Hopital Jacques Monod /ID# 152663
Montivillier, , France
Hopital de la Source /ID# 159947
Orléans, , France
Hopital de la Source /ID# 165534
Orléans, , France
Robert Debre Hopital, FR /ID# 152666
Paris, , France
Hopital Armand Trousseau /Id# 152669
Paris, , France
Hopital Armand Trousseau /Id# 157092
Paris, , France
Necker Hopital, FR /ID# 152830
Paris, , France
Chu Lyon Sud /Id# 152838
Pierre-Bénite, , France
CHU de Rennes - Hospital Sud /ID# 152730
Rennes, , France
Charles Nicolle Hosp chu rouen /ID# 152670
Rouen, , France
Charles Nicolle Hosp chu rouen /ID# 158688
Rouen, , France
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
clinical study report synopsis
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P15-759
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.